Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' SELLERS EM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 104 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Ramamoorthy, Y; Tyndale, RF; Sellers, EM
      Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates

      PHARMACOGENETICS
    2. Wong, JMY; Harper, PA; Meyer, UA; Bock, KW; Morike, K; Lagueux, J; Ayotte, P; Tyndale, RF; Sellers, EM; Manchester, DK; Okey, AB
      Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro

      PHARMACOGENETICS
    3. Tomkins, DM; Sellers, EM
      Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence

      CANADIAN MEDICAL ASSOCIATION JOURNAL
    4. Zhang, WJ; Kilicarslan, T; Tyndale, RF; Sellers, EM
      Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific andselective CYP2A6 inhibitors in vitro

      DRUG METABOLISM AND DISPOSITION
    5. Kilicarslan, T; Haining, RL; Rettie, AE; Busto, U; Tyndale, RF; Sellers, EM
      Flunitrazepam metabolism by cytochrome P450S2C19 and 3A4

      DRUG METABOLISM AND DISPOSITION
    6. Tyndale, RF; Sellers, EM
      Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk

      DRUG METABOLISM AND DISPOSITION
    7. Howard, LA; Micu, AL; Sellers, EM; Tyndale, RF
      Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    8. Gaedigk, A; Casley, WL; Tyndale, RF; Sellers, EM; Jurima-Romet, M; Leeder, JS
      Cytochrome P4502C9 (CYP2C9) allele frequencies in canadian native indian and inuit populations

      CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
    9. Schoedel, KA; Sellers, EM; Tyndale, RF
      Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain

      BIOCHEMICAL PHARMACOLOGY
    10. Vandenbergh, DJ; Thompson, MD; Cook, EH; Bendahhou, E; Nguyen, T; Krasowski, MD; Zarrabian, D; Comings, D; Sellers, EM; Tyndale, RF; George, SR; O'Dowd, BF; Uhl, GR
      Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivitydisorder populations

      MOLECULAR PSYCHIATRY
    11. Baylon, GJ; Kaplan, HL; Somer, G; Busto, UE; Sellers, EM
      Comparative abuse liability of intravenously administered remifentanil andfentanyl

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    12. Busto, UE; Kaplan, HL; Wright, CE; Gomez-Mancilla, B; Zawertailo, L; Greenblatt, DJ; Sellers, EM
      A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    13. Kathiramalainathan, K; Kaplan, HL; Romach, MK; Busto, UE; Li, NY; Sawe, J; Tyndale, RF; Sellers, EM
      Inhibition of cytochrome P450 2D6 modifies codeine abuse liability

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    14. Busto, UE; Bremner, KE; Knight, K; terBrugge, K; Sellers, EM
      Long-term benzodiazepine therapy does not result in brain abnormalities

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    15. Romach, MK; Otton, SV; Somer, G; Tyndale, RF; Sellers, EM
      Cytochrome P450 2D6 and treatment of codeine dependence

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    16. Romach, MK; Sellers, EM; Kaplan, HL; Somer, GR; Gomez-Mancilla, B
      Efficacy of dexfenfluramine in the treatment of alcohol dependence

      ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
    17. Miksys, S; Rao, Y; Sellers, EM; Kwan, M; Mendis, D; Tyndale, RF
      Regional and cellular distribution of CYP2D subfamily members in rat brain

      XENOBIOTICA
    18. Rao, YS; Hoffmann, E; Zia, M; Bodin, L; Zeman, M; Sellers, EM; Tyndale, RF
      Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking

      MOLECULAR PHARMACOLOGY
    19. Sellers, EM; Kaplan, HL; Tyndale, RF
      Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    20. Kilicarslan, T; Sellers, EM
      Lack of interaction of buprenorphine with flunitrazepam metabolism

      AMERICAN JOURNAL OF PSYCHIATRY
    21. Lelas, S; Wegert, S; Otton, SV; Sellers, EM; France, CP
      Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys

      DRUG AND ALCOHOL DEPENDENCE
    22. Ozdemir, V; Tyndale, RF; Reed, K; Herrmann, N; Sellers, EM; Kalow, W; Naranjo, CA
      Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    23. Sproule, BA; Busto, UE; Somer, G; Romach, MK; Sellers, EM
      Characteristics of dependent and nondependent regular users of codeine

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    24. Romach, MK; Sproule, BA; Sellers, EM; Somer, G; Busto, UE
      Long-term codeine use is associated with depressive symptoms

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    25. Tyndale, RF; Li, Y; Li, NY; Messina, E; Miksys, S; Sellers, EM
      Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan

      DRUG METABOLISM AND DISPOSITION
    26. Romach, MK; Glue, P; Kampman, K; Kaplan, HL; Somer, GR; Poole, S; Clarke, L; Coffin, V; Cornish, J; O'Brien, CP; Sellers, EM
      Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)

      ARCHIVES OF GENERAL PSYCHIATRY
    27. GAEDIGK A; TYNDALE RF; JURIMAROMET M; SELLERS EM; GRANT DM; LEEDER JM
      NAD(P)H-QUINONE OXIDOREDUCTASE - POLYMORPHISMS AND ALLELE FREQUENCIESIN CAUCASIAN, CHINESE AND CANADIAN NATIVE INDIAN AND INUIT POPULATIONS

      Pharmacogenetics
    28. DROLL K; BRUCEMENSAH K; OTTON SV; GAEDIGK A; SELLERS EM; TYNDALE RF
      COMPARISON OF 3 CYP2D6 PROBE SUBSTRATES AND GENOTYPE IN GHANAIANS, CHINESE AND CAUCASIANS

      Pharmacogenetics
    29. Tyndale, RF; Droll, KP; Sellers, EM
      Relevance of deficient CYP2D6 in opiate dependence

      PHARMACOGENETICS
    30. ZAWERTAILO LA; KAPLAN HL; BUSTO UE; TYNDALE RF; SELLERS EM
      PSYCHOTROPIC EFFECTS OF DEXTROMETHORPHAN ARE ALTERED BY THE CYP2D6 POLYMORPHISM - A PILOT-STUDY

      Journal of clinical psychopharmacology
    31. OZDEMIR V; NARANJO CA; SHULMAN RW; HERRMANN N; SELLERS EM; REED K; KALOW W
      DETERMINANTS OF INTERINDIVIDUAL VARIABILITY AND EXTENT OF CYP2D6 AND CYP1A2 INHIBITION BY PAROXETINE AND FLUVOXAMINE IN-VIVO

      Journal of clinical psychopharmacology
    32. ROMACH MK; KAPLAN HL; BUSTO UE; SOMER G; SELLERS EM
      A CONTROLLED TRIAL OF ONDANSETRON, A 5-HT3 ANTAGONIST, IN BENZODIAZEPINE DISCONTINUATION

      Journal of clinical psychopharmacology
    33. OZDEMIR V; NARANJO CA; HERRMANN N; SHULMAN RW; SELLERS EM; REED K; KALOW W
      THE EXTENT AND DETERMINANTS OF CHANGES IN CYP2D6 AND CYP1A2 ACTIVITIES WITH THERAPEUTIC DOSES OF SERTRALINE

      Journal of clinical psychopharmacology
    34. BUCZEK Y; LE AD; SELLERS EM; TOMKINS DM
      EFFECT OF PENTYLENETETRAZOLE ON ETHANOL INTAKE, ETHANOL KINETICS, ANDSOCIAL-BEHAVIOR IN MALE WISTAR RATS

      Alcoholism, clinical and experimental research
    35. SELLERS EM
      PHARMACOGENETICS AND ETHNORACIAL DIFFERENCES IN SMOKING

      JAMA, the journal of the American Medical Association
    36. SELLERS EM; TOMKINS DM; LE AD; ROMACH MK
      INTERACTION OF SEROTONIN WITH OTHER NEUROTRANSMITTERS - IMPLICATIONS FOR TREATMENT

      Naunyn-Schmiedeberg's archives of pharmacology
    37. PIANEZZA ML; SELLERS EM; TYNDALE RF
      NICOTINE METABOLISM DEFECT REDUCES SMOKING

      Nature
    38. NOWAK MP; SELLERS EM; TYNDALE RF
      CANADIAN NATIVE INDIANS EXHIBIT UNIQUE CYP2A6 AND CYP2C19 MUTANT ALLELE FREQUENCIES

      Clinical pharmacology and therapeutics
    39. GAEDIGK A; TYNDALE RF; JURIMAROMET M; SELLERS EM; LEEDER JS
      GENETIC POLYMORPHISMS IN THE NAD(P)H - QUINONE OXIDOREDUCTASE (NQO1) GENE LOCUS

      Clinical pharmacology and therapeutics
    40. PIANEZZA ML; SELLERS EM; TYNDALE RF
      GENETICALLY VARIABLE CYP2A6 INFLUENCES SMOKING-BEHAVIOR

      Clinical pharmacology and therapeutics
    41. ZEMAN MV; PIANEZZA ML; LI NY; TYNDALE RF; SELLERS EM
      CHARACTERIZATION OF CYP2A6 ACTIVITY USING PLASMA COUMARIN MEASUREMENTS

      Clinical pharmacology and therapeutics
    42. ZAWERTAILO LA; BUSTO UE; TYNDALE RF; SELLERS EM
      DEXTROMETHORPHANS ACTIVE METABOLITE CONTRIBUTES TO ITS ABUSE LIABILITY

      Clinical pharmacology and therapeutics
    43. KILICARSLAN T; LI NY; BUSTO U; TYNDALE RF; SELLERS EM
      FLUNITRAZEPAM - POLYMORPHIC METABOLISM BY CYP2C19

      Clinical pharmacology and therapeutics
    44. BUSTO UE; SELLERS EM; KAPLAN HL; WRIGHT CE; GREENBLATT DJ
      PHARMACOKINETIC PHARMACODYNAMIC EVALUATION OF ALPRAZOLAM SUSTAINED-RELEASE, BROMAZEPAM (B) AND LORAZEPAM (L)/

      Clinical pharmacology and therapeutics
    45. SELLERS EM; BUSTO UE; KAPLAN HL; SOMER G; BAYLON GJ
      COMPARATIVE ABUSE LIABILITY OF CODEINE AND NARATRIPTAN

      Clinical pharmacology and therapeutics
    46. CHEUNG S; NOLTE H; OTTON SV; TYNDALE RF; WU PH; SELLERS EM
      SIMULTANEOUS GAS-CHROMATOGRAPHIC DETERMINATION OF METHAMPHETAMINE, AMPHETAMINE AND THEIR P-HYDROXYLATED METABOLITES IN PLASMA AND URINE

      Journal of chromatography B. Biomedical sciences and applications
    47. TYNDALE RF; DROLL KP; SELLERS EM
      GENETICALLY DEFICIENT CYP2D6 METABOLISM PROVIDES PROTECTION AGAINST ORAL OPIATE DEPENDENCE

      Pharmacogenetics
    48. NOWAK MP; TYNDALE RF; SELLERS EM
      CYP2D6 PHENOTYPE AND GENOTYPE IN A CANADIAN NATIVE INDIAN POPULATION

      Pharmacogenetics
    49. NOWAK MP; TYNDALE RF; SELLERS EM
      CYP2D6 PHENOTYPE AND GENOTYPE IN A CANADIAN NATIVE INDIAN POPULATION

      Pharmacogenetics
    50. CHOW BLC; SELLERS EM; TOMKINS DM
      EFFECT OF NALTREXONE AND ITS DERIVATIVES, NALMEFENE AND NALTRINDOLE, ON CONDITIONED ANTICIPATORY BEHAVIOR AND SACCHARIN INTAKE IN RATS

      Behavioural pharmacology
    51. TOMKINS DM; OTTON SV; JOHARCHI N; BERNS T; WU D; CORRIGALL WA; SELLERS EM
      EFFECT OF CYP2D1 INHIBITION ON THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE

      Behavioural pharmacology
    52. LI Y; LI NY; SELLERS EM
      COMPARISON OF CYP2A6 CATALYTIC ACTIVITY ON COUMARIN 7-HYDROXYLATION IN HUMAN AND MONKEY LIVER-MICROSOMES

      European journal of drug metabolism and pharmacokinetics
    53. LI NY; LI Y; SELLERS EM
      AN IMPROVED HPLC METHOD FOR ANALYSIS OF METHAMPHETAMINE AND ITS METABOLITES IN PLASMA

      European journal of drug metabolism and pharmacokinetics
    54. SPROULE BA; OTTON SV; CHEUNG SW; ZHONG XH; ROMACH MK; SELLERS EM
      CYP2D6 INHIBITION IN PATIENTS TREATED WITH SERTRALINE

      Journal of clinical psychopharmacology
    55. BUCZEK Y; TOMKINS DM; LE AD; SELLERS EM
      OPPOSITE EFFECTS OF RO-15-4513 ON ACQUISITION AND MAINTENANCE OF ETHANOL DRINKING BEHAVIOR IN MALE WISTAR RATS

      Alcoholism, clinical and experimental research
    56. LE AD; TOMKINS D; HIGGINS G; QUAN B; SELLERS EM
      EFFECTS OF 5-HT3, D-1 AND D-2 RECEPTOR ANTAGONISTS ON ETHANOL-INDUCEDAND COCAINE-INDUCED LOCOMOTION

      Pharmacology, biochemistry and behavior
    57. MESSINA ES; TYNDALE RF; SELLERS EM
      A MAJOR ROLE FOR CYP2A6 IN NICOTINE C-OXIDATION BY HUMAN LIVER-MICROSOMES

      The Journal of pharmacology and experimental therapeutics
    58. KAPLAN HL; BUSTO UE; BAYLON GJ; CHEUNG SW; OTTON SV; SOMER G; SELLERS EM
      INHIBITION OF CYTOCHROME-P450 2D6 METABOLISM OF HYDROCODONE TO HYDROMORPHONE DOES NOT IMPORTANTLY AFFECT ABUSE LIABILITY

      The Journal of pharmacology and experimental therapeutics
    59. TOMKINS DM; OTTON SV; JOHARCHI N; LI NY; BALSTER RF; TYNDALE RF; SELLERS EM
      EFFECT OF CYTOCHROME-P450 2D1 INHIBITION ON HYDROCODONE METABOLISM AND ITS BEHAVIORAL CONSEQUENCES IN RATS

      The Journal of pharmacology and experimental therapeutics
    60. OZDEMIR V; NARANJO CA; HERRMANN N; REED K; SELLERS EM; KALOW W
      PAROXETINE POTENTIATES THE CENTRAL-NERVOUS-SYSTEM SIDE-EFFECTS OF PERPHENAZINE - CONTRIBUTION OF CYTOCHROME P4502D6 INHIBITION IN-VIVO

      Clinical pharmacology and therapeutics
    61. OZDEMIR V; NARANJO CA; HERRMANN N; SHULMAN RW; SELLERS EM; KALOW W
      SERTRALINE EFFECTS ON CYP1A2 AND CYP2D6 ISOZYME ACTIVITIES IN YOUNGERADULTS AND THE ELDERLY

      Clinical pharmacology and therapeutics
    62. OZDEMIR V; NARANJO CA; SHULMAN RW; HERRMANN N; SELLERS EM; KALOW W
      AN IN-VIVO COMPARISON OF PAROXETINE AND FLUVOXAMINE - EFFECTS ON CYP1A2 AND CYP2D6 ACTIVITIES

      Clinical pharmacology and therapeutics
    63. TYNDALE RF; DROLL K; PAK A; SELLERS EM
      ROLE OF THE CYP2D6 POLYMORPHISM IN TOBACCO DEPENDENCE

      Clinical pharmacology and therapeutics
    64. ROMACH MK; KATHIRAMALAINATHAN K; KAPLAN HL; BUSTO UE; TYNDALE RF; SELLERS EM
      CODEINE ABUSE LIABILITY IS MODIFIED BY CYP2D6 INHIBITION

      Clinical pharmacology and therapeutics
    65. SELLERS EM; KAPLAN HL; SOMER G; TYNDALE RF
      TOBACCO AND OTHER DRUG-DEPENDENCE INCREASES VARIATION IN CYTOCHROME-P450 3A ACTIVITY (CYP3A) IN FEMALES

      Clinical pharmacology and therapeutics
    66. WU DF; OTTON SV; INABA T; KALOW W; SELLERS EM
      INTERACTIONS OF AMPHETAMINE ANALOGS WITH HUMAN LIVER CYP2D6

      Biochemical pharmacology
    67. LE AD; TOMKINS DM; SELLERS EM
      USE OF SEROTONIN (5-HT) AND OPIATE-BASED DRUGS IN THE PHARMACOTHERAPYOF ALCOHOL DEPENDENCE - AN OVERVIEW OF THE PRECLINICAL DATA

      Alcohol and alcoholism
    68. OTTON SV; BALL SE; CHEUNG SW; INABA T; RUDOLPH RL; SELLERS EM
      VENLAFAXINE OXIDATION IN-VITRO IS CATALYZED BY CYP2D6

      British journal of clinical pharmacology
    69. BUSTO UE; ROMACH MK; SELLERS EM
      MULTIPLE-DRUG USE AND PSYCHIATRIC COMORBIDITY IN PATIENTS ADMITTED TOTHE HOSPITAL WITH SEVERE BENZODIAZEPINE DEPENDENCE

      Journal of clinical psychopharmacology
    70. OCAMPO JA; BUSTO UE; KAPLAN HL; TYNDALE RF; OTTON SV; NOLTE H; SYMANZIK C; SELLERS EM
      DOES EXTENT OF P-HYDROXYLATION ALTER METHAMPHETAMINE KINETICS

      Clinical pharmacology and therapeutics
    71. BUSTO UE; SPROULE BA; KNIGHT K; CHEUNG C; ROMACH MK; SELLERS EM
      SEVERE DEPENDENCE ON ORAL OPIATES

      Clinical pharmacology and therapeutics
    72. SPROULE BA; BUSTO U; GRACIAS D; ROMACH MK; SELLERS EM
      PSYCHIATRIC COMORBIDITY AND DEPENDENCE IN REGULAR USERS OF CODEINE

      Clinical pharmacology and therapeutics
    73. GOMEZMANCILLA B; CHEUNG S; OTTON SV; SELLERS EM
      BLOCKAGE OF THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF HYDROCODONE BY QUININE ADMINISTRATION

      The FASEB journal
    74. SCHADEL M; WU DA; OTTON SV; KALOW W; SELLERS EM
      PHARMACOKINETICS OF DEXTROMETHORPHAN AND METABOLITES IN HUMANS - INFLUENCE OF THE CYPBDB PHENOTYPE AND QUINIDINE INHIBITION

      Journal of clinical psychopharmacology
    75. ZAWERTAILO LA; BUSTO U; KAPLAN HL; SELLERS EM
      COMPARATIVE ABUSE LIABILITY OF SERTRALINE, ALPRAZOLAM, AND DEXTROAMPHETAMINE IN HUMANS

      Journal of clinical psychopharmacology
    76. SELLERS EM
      TREATMENT OF THE ACUTE ALCOHOL-WITHDRAWAL STATE - A COMPARISON OF 4 DRUGS - COMMENT

      Alcohol health and research world
    77. WU DF; OTTON SV; KALOW W; SELLERS EM
      EFFECTS OF ROUTE OF ADMINISTRATION ON DEXTROMETHORPHAN PHARMACOKINETICS AND BEHAVIORAL-RESPONSE IN THE RAT

      The Journal of pharmacology and experimental therapeutics
    78. SPROULE BA; OTTON SV; CHEUNG SW; ZONG XH; ROMACH MK; SELLERS EM
      DOES SERTRALINE INHIBIT CYP2D6 AFTER CHRONIC DOSING

      Clinical pharmacology and therapeutics
    79. SPROULE BA; BUSTO UE; OTTON SV; ZHONG XH; SELLERS EM
      ABUSE AND DEPENDENCE ON PRESCRIPTION OPIATES

      Clinical pharmacology and therapeutics
    80. WANG Y; JOHARCHI N; FLETCHER PJ; SELLERS EM; HIGGINS GA
      FURTHER-STUDIES TO EXAMINE THE NATURE OF DEXFENFLURAMINE-INDUCED SUPPRESSION OF HEROIN SELF-ADMINISTRATION

      Psychopharmacology
    81. TOMKINS DM; LE AD; SELLERS EM
      EFFECT OF THE 5-HT3 ANTAGONIST ONDANSETRON ON VOLUNTARY ETHANOL INTAKE IN RATS AND MICE MAINTAINED ON A LIMITED ACCESS PROCEDURE

      Psychopharmacology
    82. BUCZEK Y; TOMKINS DM; HIGGINS GA; SELLERS EM
      DISSOCIATION OF SEROTONERGIC REGULATION OF ANXIETY AND ETHANOL SELF-ADMINISTRATION - A STUDY WITH MCPP

      Behavioural pharmacology
    83. SELLERS EM; TONEATTO T; ROMACH MK; SOMER GR; SOBELL LC; SOBELL MB
      CLINICAL EFFICACY OF THE 5-HT3 ANTAGONIST ONDANSETRON IN ALCOHOL-ABUSE AND DEPENDENCE

      Alcoholism, clinical and experimental research
    84. HIGGINS GA; SILLS TL; TOMKINS DM; SELLERS EM; VACCARINO FJ
      EVIDENCE FOR THE CONTRIBUTION OF CCKB RECEPTOR MECHANISMS TO INDIVIDUAL-DIFFERENCES IN AMPHETAMINE-INDUCED LOCOMOTION

      Pharmacology, biochemistry and behavior
    85. HIGGINS GA; SELLERS EM
      ANTAGONIST-PRECIPITATED OPIOID WITHDRAWAL IN RATS - EVIDENCE FOR DISSOCIATIONS BETWEEN PHYSICAL AND MOTIVATIONAL SIGNS

      Pharmacology, biochemistry and behavior
    86. HIGGINS GA; TOMKINS DM; POULOS CX; SELLERS EM
      EFFECT OF DEXFENFLURAMINE ON SACCHARIN DRINKING - BEHAVIORAL AND PHARMACOLOGICAL STUDIES

      Pharmacology, biochemistry and behavior
    87. TOMKINS DM; SELLERS EM; FLETCHER PJ
      MEDIAN AND DORSAL RAPHE INJECTIONS OF THE 5-HT1A AGONIST, 8-OH-DPAT, AND THE GABA(A), AGONIST, MUSCIMOL, INCREASE VOLUNTARY ETHANOL INTAKE IN WISTAR RATS

      Neuropharmacology
    88. BUSTO U; KAPLAN HL; ZAWERTAILO L; SELLERS EM
      PHARMACOLOGICAL EFFECTS AND ABUSE LIABILITY OF BRETAZENIL, DIAZEPAM, AND ALPRAZOLAM IN HUMANS

      Clinical pharmacology and therapeutics
    89. ZAWERTAILO L; BUSTO U; KAPLAN HL; SELLERS EM
      COMPARATIVE ABUSE LIABILITY OF MEPROBAMATE, BUTABARBITAL AND TRIAZOLAM IN RECREATIONAL DRUG-USERS

      Clinical pharmacology and therapeutics
    90. OTTON SV; BALL SE; CHEUNG SW; INABA T; SELLERS EM
      COMPARATIVE INHIBITION OF THE POLYMORPHIC ENZYME CYP2D6 BY VENLAFAXINE (VF) AND OTHER 5HT UPTAKE INHIBITORS

      Clinical pharmacology and therapeutics
    91. HIGGINS GA; JOHARCHI N; WANG Y; CORRIGALL WA; SELLERS EM
      THE CCK(A) RECEPTOR ANTAGONIST DEVAZEPIDE DOES NOT MODIFY OPIOID SELF-ADMINISTRATION OR DRUG DISCRIMINATION - COMPARISON WITH THE DOPAMINE ANTAGONIST HALOPERIDOL

      Brain research
    92. TOMKINS DM; HIGGINS GA; SELLERS EM
      LOW-DOSES OF THE 5-HT1A AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN (8-OH DPAT) INCREASE ETHANOL INTAKE

      Psychopharmacology
    93. HIGGINS GA; WANG YP; CORRIGALL WA; SELLERS EM
      INFLUENCE OF 5-HT3 RECEPTOR ANTAGONISTS AND THE INDIRECT 5-HT AGONIST, DEXFENFLURAMINE, ON HEROIN SELF-ADMINISTRATION IN RATS

      Psychopharmacology
    94. SCHADEL M; ROMACH MK; SELLERS EM
      MANIA AND COUGH SYRUP

      The Journal of clinical psychiatry
    95. GREENBLATT DJ; VONMOLTKE LL; HARMATZ JS; CIRAULO DA; SHADER RI; SELLERS EM; BALLENGER JC; SCHATZBERG; WEISSMAN; SHEAR
      ALPRAZOLAM PHARMACOKINETICS, METABOLISM, AND PLASMA-LEVELS - CLINICALIMPLICATIONS

      The Journal of clinical psychiatry
    96. BALLENGER JC; PECKNOLD J; RICKELS K; SELLERS EM; SCHATZBERG; SHADER RI; SHEAR; WEISSMAN
      MEDICATION DISCONTINUATION IN PANIC DISORDER

      The Journal of clinical psychiatry
    97. JONAS JM; COHON MS; WEISSMAN; BARBEE JG; KRAVITZ HM; SHADER RI; GREENBLATT; SELLERS EM; SHEAR
      A COMPARISON OF THE SAFETY AND EFFICACY OF ALPRAZOLAM VERSUS OTHER AGENTS IN THE TREATMENT OF ANXIETY, PANIC, AND DEPRESSION - A REVIEW OF THE LITERATURE

      The Journal of clinical psychiatry
    98. COLE JO; KANDO JC; SCHATZBERG; BALLENGER JC; SHADER RI; SHEAR; GREENBLATT DJ; SELLERS EM
      ADVERSE BEHAVIORAL EVENTS REPORTED IN PATIENTS TAKING ALPRAZOLAM AND OTHER BENZODIAZEPINES

      The Journal of clinical psychiatry
    99. SELLERS EM; CIRAULO DA; DUPONT RL; GRIFFITHS RR; KOSTEN TR; ROMACH MK; WOODY GE; SHADER RI; SHEAR; GREENBLATT DJ; BALLENGER JC; SCHATZBERG; BARBEE JG
      ALPRAZOLAM AND BENZODIAZEPINE DEPENDENCE

      The Journal of clinical psychiatry
    100. HIGGINS GA; WANG YH; SELLERS EM
      PRELIMINARY FINDINGS WITH THE INDIRECT 5-HT AGONIST DEXFENFLURAMINE ON HEROIN DISCRIMINATION AND SELF-ADMINISTRATION IN RATS

      Pharmacology, biochemistry and behavior


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 07:25:30